Dr. Seema A. Bhat
Claim this profileOhio State University Comprehensive Cancer Center
Studies Lymphoma
Studies T-Lymphoblastic Leukemia/Lymphoma
2 reported clinical trials
4 drugs studied
Area of expertise
1Lymphoma
13q positive
13q negative
12 positive
2T-Lymphoblastic Leukemia/Lymphoma
13q positive
13q negative
12 positive
Affiliated Hospitals
Clinical Trials Seema A. Bhat is currently running
Pneumococcal Vaccination
for Chronic Lymphocytic Leukemia
This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vaccination. Current vaccination schedule for chronic lymphocytic leukemia patients is based on general recommendations in immunocompromised patients (initial vaccination with PCV13 followed by one dose of PSV23 after an interval of two months, followed by revaccination at 5 years). Giving patients frequent immunization as compared to 5 year immunization may result in higher protective titers in patients.
Recruiting2 awards Phase 2
Venetoclax + Obinutuzumab
for Leukemia
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
Recruiting2 awards Phase 31 criteria
More about Seema A. Bhat
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Seema A. Bhat has experience with
- Pneumococcal 13-valent Conjugate Vaccine
- Pneumococcal Polyvalent Vaccine
- Obinutuzumab
- Venetoclax
Breakdown of trials Seema A. Bhat has run
Lymphoma
T-Lymphoblastic Leukemia/Lymphoma
Lymphoid Leukemia
Chronic Lymphocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Seema A. Bhat specialize in?
Seema A. Bhat focuses on Lymphoma and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Lymphoma has involved 13q positive patients, or patients who are 13q negative.
Is Seema A. Bhat currently recruiting for clinical trials?
Yes, Seema A. Bhat is currently recruiting for 2 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Seema A. Bhat has studied deeply?
Yes, Seema A. Bhat has studied treatments such as Pneumococcal 13-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine, Obinutuzumab.
What is the best way to schedule an appointment with Seema A. Bhat?
Apply for one of the trials that Seema A. Bhat is conducting.
What is the office address of Seema A. Bhat?
The office of Seema A. Bhat is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.